论文部分内容阅读
目的探讨老年乳腺浸润性导管癌不同分子分型的临床特征及预后。方法老年乳腺浸润性导管癌患者63例,分为Luminal A型(27例)、Luminal B型(15例)、HER-2过表达型(10例)和三阴性型(11例),记录其局部复发和远处转移情况,分析不同分子分型的临床病理特征及预后。结果 63例患者中,局部复发患者5例,远处转移患者11例。HER-2过表达型的局部复发率(20.00%vs.3.70%、6.67%和9.09%)和远处转移率(40.00%vs.11.11%、13.33%和18.18%)高于Luminal A型、Luminal B型和三阴性型(P<0.05),无病生存率及总生存率低于其他分子分型(P<0.05)。结论老年乳腺浸润性导管癌患者HER-2过表达型有较高的局部复发和远处转移率,且预后较差。
Objective To investigate the clinical characteristics and prognosis of infiltrating ductal carcinoma of the elderly with different molecular types. Methods Sixty-three elderly patients with breast invasive ductal carcinoma were divided into Luminal A type (27 cases), Luminal B type (15 cases), HER-2 overexpression type (10 cases) and triple negative type (11 cases) Local recurrence and distant metastasis, analysis of different molecular types of clinical and pathological features and prognosis. Results Among the 63 patients, there were 5 patients with local recurrence and 11 patients with distant metastasis. The local recurrence rates of HER-2 overexpression (20.00% vs.3.70%, 6.67% and 9.09%) and distant metastasis (40.00% vs.11.11%, 13.33% and 18.18%) were higher than those of Luminal A, Luminal B type and triple negative type (P <0.05). The disease-free survival rate and overall survival rate were lower than other molecular types (P <0.05). Conclusion The overexpression of HER-2 in elderly patients with invasive ductal carcinoma has a higher rate of local recurrence and distant metastasis, and the prognosis is poor.